Respirology Search
Respirology Respirology
pneumonia%20-%20hospital-acquired
PNEUMONIA - HOSPITAL-ACQUIRED
Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after admission and excluding any infection that is incubating at the time of admission.
Ventilator-associated pneumonia (VAP) is described as pneumonia occurring >48-72 hours after endotracheal intubation and within 48 hours after removal of endotracheal tube.
Early-onset HAP or VAP is the pneumonia occurring within the first 4 days of hospitalization that may be cause by antibiotic-sensitive bacteria that usually carries a better diagnosis.
Late-onset HAP or VAP is the pneumonia occurring after ≥5 days. It is likely caused by multidrug-resistant pathogens associated with increased mortality and morbidity.

Pneumonia - Hospital-Acquired Drug Information

Drug Information

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections of the resp tract, middle ear (otitis media), paranasal sinuses (sinusitis) especially caused by gm...

Indication: Upper & lower resp tract infection, upper & lower UTI, peritonitis, cholecystitis, cholangitis & o...

Indication: Lower resp tract, complicated & uncomplicated UTI, intra-abdominal, skin & skin structure infections; ...

Indication: Upper & lower resp tract infections including sinusitis, otitis media, epiglottitis, bacterial pneumonia, ...

Indication: Upper resp tract infections including sinusitis, otitis media, tonsillitis; lower resp tract infections includ...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: Nosocomial & community-acquired pneumonia including concurrent bacteremia; complicated & uncomplicated...

1  /  21
1  /  21
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Mavrilimumab improves outcomes in COVID-19 pneumonia with hyperinflammation
Audrey Abella, 03 Aug 2020
Adding the anti-GM-CSF* receptor-α monoclonal antibody mavrilimumab to standard care (SC) improved clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia and systemic hyperinflammation who were not under mechanical ventilation (MV), an Italian study has shown.
Oral as good as IV antibiotics for ridding P aeruginosa in cystic fibrosis
Pearl Toh, 08 Dec 2020
Intravenous (IV) antibiotics are no better than oral antibiotics when it comes to eradicating Pseudomonas (P.) aeruginosa in children and adults with cystic fibrosis, yet are more costly than the latter, reveals the TORPEDO-CF study.
Hexavalent, pneumococcal vaccine update included in national immunisation schedule
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.
Having asthma or allergy does not increase risk for severe COVID-19
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.